196 related articles for article (PubMed ID: 2584406)
1. Findings in lymph nodes of patients with germ cell tumours after chemotherapy and their relation to prognosis.
Zuk RJ; Jenkins BJ; Martin JE; Oliver RT; Baithun SI
J Clin Pathol; 1989 Oct; 42(10):1049-54. PubMed ID: 2584406
[TBL] [Abstract][Full Text] [Related]
2. [A case of teratoma of the testis with retroperitoneal lymph nodes involved with malignant teratoma after chemotherapy].
Muraki J; Nakazono M
Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2162-5. PubMed ID: 7508531
[TBL] [Abstract][Full Text] [Related]
3. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer.
Fosså SD; Aass N; Ous S; Høie J; Stenwig AE; Lien HH; Paus E; Kaalhus O
J Urol; 1989 Nov; 142(5):1239-42. PubMed ID: 2478726
[TBL] [Abstract][Full Text] [Related]
4. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of metastases from testicular germ cell tumours using fine needle aspiration cytology.
Highman WJ; Oliver RT
J Clin Pathol; 1987 Nov; 40(11):1324-33. PubMed ID: 3693570
[TBL] [Abstract][Full Text] [Related]
6. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer.
Fosså SD; Ous S; Lien HH; Stenwig AE
J Urol; 1989 Mar; 141(3):557-9. PubMed ID: 2918591
[TBL] [Abstract][Full Text] [Related]
7. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J
Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079
[TBL] [Abstract][Full Text] [Related]
8. [Mature teratoma following chemotherapy in bilateral testicular tumors--a critical contribution].
Fichte A; von Paris V
Z Urol Nephrol; 1985 Jun; 78(6):317-21. PubMed ID: 4036384
[TBL] [Abstract][Full Text] [Related]
9. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
10. Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
Calaminus G; Schneider DT; Weissbach L; Schönberger S; Okpanyi V; Leuschner I; Poremba C; Göbel U
Klin Padiatr; 2009; 221(3):136-40. PubMed ID: 19437360
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors of the testis.
Jacqmin D
Eur Urol; 2008 Feb; 53(2):272-3. PubMed ID: 18045771
[No Abstract] [Full Text] [Related]
13. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection.
Johnston P; Beck SD; Cheng L; Masterson TA; Bihrle R; Kesler K; Foster RS
J Urol; 2013 Sep; 190(3):874-7. PubMed ID: 23517745
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapeutic effectiveness in malignant testicular tumors at advanced stages. Preliminary results of the VAB VI program].
Chiricuţă I; Ghilezan N
Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1985; 34(6):455-68. PubMed ID: 2421373
[No Abstract] [Full Text] [Related]
15. Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer tumors of the testis.
Culine S
Eur Urol; 2008 Feb; 53(2):273-4. PubMed ID: 18045772
[No Abstract] [Full Text] [Related]
16. Retroperitoneal lymph node dissection (RPLND) post chemotherapy for non-seminomatous testicular neoplasms: what is the significance of residual masses at scanner control after chemotherapy and should they be removed?
Solé-Balcells F; Villavicencio H; Germá R
Prog Clin Biol Res; 1989; 303():759-62. PubMed ID: 2780671
[No Abstract] [Full Text] [Related]
17. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
Djaladat H; Nichols C; Daneshmand S
Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
[TBL] [Abstract][Full Text] [Related]
19. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours.
Harding MJ; Brown IL; MacPherson SG; Turner MA; Kaye SB
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1689-94. PubMed ID: 2561098
[TBL] [Abstract][Full Text] [Related]
20. [Experiences in the treatment of advanced nonseminomatous testicular tumor].
Scheiber K; Salzer M; Bartsch G
Wien Klin Wochenschr; 1986 Aug; 98(15):481-6. PubMed ID: 2429460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
